It’s a rare thing
to care
Cutting-edge drugs for
calcium-related diseases
FIND MORE >
Ca++
is a crucial ion
in the regulation of numerous cellular processes in the human cells.
Its homeostasis is attentively regulated by several mechanisms, including the SOCE*.
*Store-Operated Calcium Entry
SOCE disregulation
leads to an unusual increase of intracellular Ca++ and is related to rare diseases such as
Tubular Aggregate Myopathies
1 : 100,000
globalprevalence
Duchenne Muscular Dystrophy
1 : 3,300
male globalincidence
and autoimmune and inflammatory diseases such as
Multiple Sclerosis
Rheumatoid Arthritis
Lupus
Atopic Dermatitis
Our cutting-edge
molecules
are innovative and highly selective chemical inhibitors of SOCE.
They are capable of reducing SOCE activity in a nanomolar range and therefore can be safely used as a treatment for related pathologies.
Good safety &
PK profile
IP
protection
Easy manufacturing
FIND MORE
Team
Nicola Pastori
Financial Analyst
Our values
Sustainability
Addressing the current needs while safeguarding the capacity of future generations to fulfill their requirements is our imperative. Recognizing the environmental implications of our operations, we set forth explicit goals and viable solutions to meet the escalating demands responsibly.Integrity
Exemplifying sincerity and upholding unwavering commitment to robust moral and ethical standards, we remain authentic to our core, refraining from any actions that may diminish or compromise our integrity.Partners
News
24.09.24ChemiCare drug candidate CIC-39 received the FDA orphan drug designation for Duchenne Muscular Dystrophy.
Food and Drug Administration
10.09.24Beatrice Riva among the InspiringFifty Italy 2024 Winners.
Beatrice Riva, CEO of ChemiCare, was among the fifty women recognized as role models this year by InspiringFifty Italy 2024.
24.06.24ChemiCare in Silicon Valley for CALL4INNOVIT.
ChemiCare was selected by INNOVIT – Italian Innovation and Culture Hub to take part at CALL4INNOVIT, the acceleration program dedicated to startup and scaleups in Life Sciences & Digital Health.
30.01.24ChemiCare and Bridge4Pharma are joining forces into a partnership to push forward the development of pipeline initiatives.
Together with this alliance, Bridge4Pharma S.r.l., decided to invest in ChemiCare S.r.l.
08.05.23ChemiCare has received the award “America Innovazione”
Corriere della Sera
08.12.22ChemiCare drug candidate CIC-39 received the EMA orphan drug designation for Duchenne Muscular Dystrophy.
European Medicine Agency- 12.05.22
ChemiCare drug candidate CIC-39 received the EMA orphan drug designation for TAM and other calcium-related disease.
European Medicine Agency 
19.11.21Modulatori del SOCE, composizioni e loro usi
Università del Piemonte Orientale
28.06.21ChemiCare – Beatrice Riva
Università del Piemonte Orientale
22.06.21Intervista alla dottoressa Beatrice Riva di ChemICare
Biotecnologie News
03.11.20ChemICare, nuova frontiera contro le malattie rare correlate al calcio
Bio4Dreams
23.02.18Chemicare: seconda posizione e menzione speciale all’Italian Patent Competition
Innogest – Deloitte – Ministero per lo Sviluppo Economico
19.01.18ChemiCare – Pharma for calcium regulation
Università del Piemonte Orientale
26.08.17Le ricercatrici a caccia di molecole che combattono le malattie rare
La Stampa
15.10.16Molecole contro le malattie rare. Premiata la ricerca novarese.
La Stampa
13.10.16La start up Chemicare parteciperà al Premio Nazionale dell’Innovazione 2016
La Stampa
04.10.16ChemiCare – Spin-off UPO
Università del Piemonte Orientale
Contact us
It's a rare thing
to care
ChemiCare S.r.l.
Registered Office: Corso Trieste 15/A, Novara, Italy
Operating Office:
MIND - Viale Decumano 41, Palazzina 8, 20157, Milano, Italy
Via Flavia 23/1 Trieste, Italy
VAT number: 02505930038
Mail: info@chemicare.it
